Markets:

Overview

News

Currencies

International

Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

50.93 +2.86 (+5.95%)

Streaming Delayed Price Updated: 3:08 PM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Alkermes Q2 Sales Up 14 Percent ↗

July 29, 2025

Via The Motley Fool

Topics Intellectual Property

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. ↗

July 21, 2025

All four companies are testing out orexin agonists to improve the symptoms of narcolpesy.

Via Investor's Business Daily

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study ↗

July 21, 2025

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability across all doses.

Via Benzinga

Expert Outlook: Alkermes Through The Eyes Of 6 Analysts ↗

July 15, 2025

Via Benzinga

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗

July 07, 2025

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Via Stocktwits

Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗

May 28, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

NASDAQ:ALKS: good value for what you're paying. ↗

February 12, 2025

Uncover the potential of ALKERMES PLC, an undervalued stock. NASDAQ:ALKS maintains a strong financial position and offers an appealing valuation.

Via Chartmill

ALKERMES PLC (NASDAQ:ALKS) – A Potential Undervalued Opportunity in Biopharma ↗

July 04, 2025

ALKERMES PLC (NASDAQ:ALKS) shows strong profitability and financial health while trading at a discount to peers, making it a potential value opportunity in biopharma.

Via Chartmill

Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 17, 2025

Via Benzinga

This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday ↗

June 17, 2025

Via Benzinga

Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗

June 17, 2025

Via Benzinga

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

May 28, 2025

Via Benzinga

Earnings Scheduled For February 12, 2025 ↗

February 12, 2025

Via Benzinga

Despite its impressive fundamentals, NASDAQ:ALKS remains undervalued. ↗

December 31, 2024

ALKERMES PLC (NASDAQ:ALKS) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

NASDAQ:ALKS, an undervalued stock with good fundamentals. ↗

December 10, 2024

ALKERMES PLC (NASDAQ:ALKS): good value for what you're paying.

Via Chartmill

Beyond The Numbers: 6 Analysts Discuss Alkermes Stock ↗

April 28, 2025

Via Benzinga

In a market where value is scarce, ALKERMES PLC (NASDAQ:ALKS) offers a refreshing opportunity with its solid fundamentals. ↗

April 17, 2025

ALKERMES PLC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:ALKS showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

What 5 Analyst Ratings Have To Say About Alkermes ↗

March 27, 2025

Via Benzinga

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday? ↗

February 12, 2025

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New...

Via Benzinga

Topics Economy

NASDAQ:ALKS: good value for what you're paying. ↗

November 18, 2024

Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents.

Via Chartmill

A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts ↗

November 05, 2024

Via Benzinga

Alkermes Plc EPS Soars Past Forecasts ↗

February 12, 2025

Alkermes reported strong earnings by exceeding both revenue and earnings expectations in its latest quarterly release.

Via The Motley Fool

NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

January 22, 2025

When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 19, 2024

Via Benzinga

Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 05, 2024

Via Benzinga

NASDAQ:ALKS is an undervalued gem with solid fundamentals. ↗

October 28, 2024

ALKERMES PLC (NASDAQ:ALKS), an undervalued stock with good fundamentals.

Via Chartmill

Alkermes's Earnings: A Preview ↗

October 23, 2024

Via Benzinga

Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗

October 14, 2024

Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.